Article Data

  • Views 588
  • Dowloads 122

Original Research

Open Access

Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer

  • J. Liang1,4,*,
  • X. Yang2,*,
  • L. Liu3,*,
  • L. Qiao4
  • P. Peng1,4
  • J. Zhou1,2

1Department of TCM Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou

2Cancer Research Institute, Southern Medical University, Guangzhou

3Department of Gynaecology, The Third Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Zhuzhou

4Department of Gynaecology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou (China)

DOI: 10.31083/j.ejgo.2020.01.4788 Vol.41,Issue 1,February 2020 pp.30-35

Published: 15 February 2020

*Corresponding Author(s): J. Liang E-mail:


Objective: This study aimed to determine the role of miR-205, miR-182, and miR-183 expression in the serum of ovarian cancer patients in the early diagnosis of ovarian cancer. Materials and Methods: The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was detected in the sera of 101 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 50 healthy volunteers. The results were validated in 98 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 53 healthy volunteers. The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was subjected to ROC analysis and binary logistic regression analysis. Results: The sensitivity of miR-182 and CA-125 was highest (0.901% and 0.832, respectively), but the specificity was low (both 0.27) in the early diagnosis of ovarian cancer. HE4 had the highest specificity in the early diagnosis of ovarian cancer. The sensitivity, specificity, and AUC of HE4 were 0.842, 0.81, and 0.847, respectively. Binary logistic regression analysis showed that three variables were suitable for the diagnostic model: Y=Logit(P)=-5.457+5.365*miR183+0.019*HE4+0.004*CA125. Based on the diagnostic model, ROC analysis showed that the sensitivity, specificity, and AUC were 0.97, 0.85, and 0.951, respectively. Statistical validation showed that the sensitivity, specificity and AUC were 0.941, 0.86, and 0.951, respectively. Conclusion: miR-183 has high specificity and sensitivity in the diagnosis of ovarian cancer. Measurement of miR-183 combined with HE4 and CA-125 is of value for the early diagnosis and evaluation of ovarian cancer.


miRNA-183; HE4; CA-125; Ovarian cancer.

Cite and Share

J. Liang,X. Yang,L. Liu,L. Qiao,P. Peng,J. Zhou. Combined measurement of miRNA-183, HE4, and CA-125 increases diagnostic efficiency for ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(1);30-35.


[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[2] Foley O.W., Rauh-Hain J.A., del Carmen M.G.: “Recurrent epithelial ovarian cancer: an update on treatment”. Oncology, 2013, 27, 288.

[3] Hall M., Gourley C., McNeish I., Ledermann J., Gore M., Jayson G., et al.: “Targeted anti-vascular therapies for ovarian cancer: current evidence”. Br. J. Cancer, 2013, 108, 250.

[4] Bian J., Li B., Kou X.J., Liu T.Z., Ming L.: “Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer”. Asian Pac. J. Cancer Prev., 2013, 14, 6241.

[5] Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., et al.: “Circulating microRNAs in plasma of patients with gastric cancers”. Br. J. Cancer, 2010, 102, 1174.

[6] Li B.S., Zhao Y.L., Guo G., Li W., Zhu E.D., Luo X., et al.: “Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection”. PLoS One, 2012, 7, 41629.

[7] Chen H.X., Zhang L., Zhang L.L., Du J., Wang H.Y., Wang B.: “MicroRNA-183 correlates cancer prognosis, regulates cancer prolifer-ation and bufalin sensitivity in epithelial ovarian caner”. Am. J. Transl. Res., 2016, 8, 1748.

[8] Marzec-Kotarska B., Cybulski M., Kotarski J.C., Ronowicz A., Tarkowski R., Polak G., et al.: “Molecular bases of aberrant miR-182 expression in ovarian cancer”. Genes Chromosomes Cancer, 2016, 55, 877.

[9] Niu K., Shen W., Zhang Y., Zhao Y., Lu Y.: “MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1”. Gene, 2015, 574, 330.

[10] Wang L., Zhu M.J., Ren A.M., Wu H.F., Han W.M., Tan R.Y., Tu R.Q.: “A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer”. PLoS One, 2014, 9, 96472.

[11] Wang Y.Q., Guo R.D., Guo R.M., Sheng W., Yin L.R.: “MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas”. J. Cell. Biochem., 2013, 114, 1464.

[12] Zheng H., Zhang L.N., Zhao Y.R., Yang D., Song F.J., Wen Y., et al.: “Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.”. PLoS One, 2013, 8, e77853.

[13] Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., et al.: “Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis”. Mol Carcinog, 2011, 50, 136.

[14] Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., et al: “Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer”. PloS one, 2014, 9, 87780.

[15] Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al: “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases”. Cell Res, 2008, 18, 997.

[16] Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al: “MicroRNA expression profiles classify human cancers”. Nature, 2005, 435, 834.

[17] Eitan R., Kushnir M., Lithwick-Yanai G., David M.B., Hoshen M., Glezerman M., et al: “Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients”. Gynecol Oncol, 2009, 114, 253.

[18] Sorrentino A., Liu C.G., Addario A., Peschle C., Scambia G., Ferlini C.: “Role of microRNAs in drug-resistant ovarian cancer cells”.Gynecol Oncol, 2008, 111, 478.

[19] Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., et al: “MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer”. Cancer Res, 2008, 68, 10307.

[20] Fang L., Du W.W., Yang W., Rutnam Z.J., Peng C., Li H., et al: “MiR-93 enhances angiogenesis and metastasis by targeting LATS2”. Cell cycle, 2012, 11, 4352.

[21] Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al.: “Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells”. Mol. Cancer, 2011, 10, 117.

[22] Jacobs I., Bast R.C., Jr.: “The CA 125 tumour-associated antigen: a review of the literature”. Hum. Reprod.,1989, 4, 1.

[23] Kirchhoff C.: “Molecular characterization of epididymal proteins”. Rev. Reprod., 1998, 3, 86.

[24] Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A, Schummer M., McIntosh M., et al.: “The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma”. Cancer Res., 2003, 63, 3695.

[25] Holcomb K., Vucetic Z., Miller M.C., Knapp R.C.: “Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women”. Am. J. Obstet. Gynecol., 2011, 205, 351.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time